Viewing nowDaparo 5 mg (Dapagliflozin Propanediol Hydrate)
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
Hanlim Pharmaceutical Co., Ltd.

MFDS item code 202204312 · Approved 2022.11.30 · Insurance code 645306840
Treatment of type 2 diabetes mellitus, chronic heart failure, and chronic kidney disease
This medication is used in conjunction with diet and exercise therapy to help control blood sugar in patients with type 2 diabetes. It also helps reduce the risk of death and hospitalization due to cardiovascular disease in patients with chronic heart failure. In patients with chronic kidney disease, it is used to slow the decline of kidney function and reduce the risk of cardiovascular and kidney-related mortality. Thus, this medication is effective not only in controlling blood sugar but also in improving heart and kidney health.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for both monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received drug treatment for diabetes, the recommended initial dose of this medicine when administered in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablets should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be administered to certain patients. It should not be used in patients with allergies to the active ingredient or excipients, patients with type 1 diabetes, patients with diabetic ketoacidosis, and patients with genetic lactose intolerance issues. Additionally, patients on dialysis should not take this medication. Patients with reduced fluid volume or kidney function problems should use this medication with caution. This medication may cause hypotension or temporary worsening of kidney function, so fluid status and kidney function should be assessed before administration, and any symptoms of hypotension or changes in kidney function should be carefully monitored after administration. In particular, caution is advised in patients with moderate or severe reductions in kidney function, as blood sugar control may be less effective. While taking this medication, side effects such as genital infections, urinary tract infections, hypoglycemia, reduced fluid volume, thirst, dizziness, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, increased hematocrit, decreased renal creatinine clearance, dyslipidemia, increased serum creatinine, increased blood urea, weight loss, urticaria, cold sweat, itching, fatigue, swelling, face swelling, facial pain, warmth, flu-like symptoms, chest pain, and fatigue may occur. Pregnant women should not use this medication, and administration should be discontinued if pregnancy is confirmed. Breastfeeding women should also avoid taking this medication, and safety and efficacy in children have not been established. This medication may interact with other drugs, so patients taking diuretics, insulin, or sulfonylureas should consult their physician. Additionally, this medication may affect blood sugar test results, so caution is needed during blood sugar monitoring. In case of overdose, appropriate symptomatic treatment is required. This medication does not significantly affect the ability to drive or operate machinery, but caution should be exercised due to the risk of hypoglycemia. Finally, this medication should be stored out of the reach of children and kept in its original container for safety.
Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, polydipsia, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar pruritus, genital pruritus, increased hematocrit, reduced renal creatinine clearance at the beginning of treatment, dyslipidemia, elevated serum creatinine at the beginning of treatment, increased blood urea, weight loss, acute pyelonephritis, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, bile duct stone, cholangitis, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, chest pain, taste abnormalities, drowsiness, tension headache, carpal tunnel syndrome, cerebral infarction, diabetic neuropathy, unconsciousness, nerve compression, neuralgia, peripheral neuropathy, sleep disorders, syncope, tremor, herpes simplex, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like syndrome, chest discomfort, fatigue, vaginal discharge, menstrual irregularities, pruritus, urticaria, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering. It is best to store it at room temperature between 1 to 30 degrees Celsius.
Yellow, biconvex, round film-coated tablet
PTP - 28 tablets/box [7 tablets/PTP X 4]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowDapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
Hanlim Pharmaceutical Co., Ltd.
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Sung IS Co., Ltd.
Dapagliflozin Propanediol Hydrate
Prescription medication
Optus Pharmaceutical Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Aprogen Biologics Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.